New Quinoline-Based Proteasome Inhibitors
There are several existing cancer treatments that are effective at inducing cell death by decreasing proteasome activity: Velcade® (bortezomib) and Kyprolis® (carfilzomib). Due to undesirable side effects and pharmacodynamics properties, these agents have been limited to treating blood cancers. MSU researchers have developed a new class of therapeutic compounds with a unique mode of action and more promising pharmacodynamics.
Description of Technology
This technology uses a new class of quinoline-based proteasome inhibitors. These compounds differ from previous proteasome inhibitors by exhibiting uncompetitive reversible inhibition rather than competitive inhibition. This technology is effective against bortezomib-resistant Multiple Myeloma cells and has potential as a novel asthma treatment.
- Effective against drug-resistant myeloma cells
- Has potential to target other cancers and diseases
- Novel mechanism of inhibition
- Simple chemical synthesis
- Treating Multiple Myeloma
- Inhibit proteasome function to kill cancer cell
- Effective against bortezomib-resistant strains
- Treating asthma
Licensing Rights Available
Full licensing rights available
Inventors: Aaron Odom, Jetze Tepe, Teri Lansdall
Tech ID: TEC2016-0123
Alternative contact due to temporary leave:
Nina (Isi) Davis, Technology Marketing Manager, email: email@example.com, phone (direct): (517)884-1829.
For Information, Contact:
Michigan State University